Oncology Committee Page

The oncology committee of the SPR is comprised of a group of dedicated pediatric radiologists to the imaging diagnosis and management of childhood cancer. We are made up of specialists from across the United States and Europe and combined, bring a breadth of knowledge to share with you. Please use this page as a resource to facilitate your own practice. If you are interested in joining the committee, please contact the SPR office or committee chairperson.

Oncologic Imaging

Known as the most common extra-cranial solid tumor of infancy, this disease has a very heterogeneous presentation and outcome. Meaning, patients with low risk disease with favorable histology do extremely well with treatment and have up to 90% survival. However, high risk patients with unfavorable histology and/or advanced stage disease have less than 40-50% long term survival. Recent advances in neuroblastoma research have focused on new therapies for high risk patients including antibody therapy and radionuclide therapy using I-131 MIBG. Newer radionuclide therapy using Lu-177 may be on the horizon. Advances in genetics will push treatment towards personalized medicine, specific to the characteristics of the individual tumor.


Additional Resources: 

The most common primary malignant liver tumor in children under age 4 years presenting with painless abdominal mass and typically marked elevation in serum alpha fetoprotein. Association with some underlying predisposition syndromes has been reported including: hemihypertophy Beckwith-Weidemann, biliary atresia, Gardner syndrome, familial polyposis and prematurity. Resectability of the primary tumor is of utmost importance and image guided staging of these tumors using the PRETEXT guidelines provides standardization for radiologists and surgeons alike.


Additional Resources:

Accounts for 1% of all cancers and is curable in almost 90%. The bimodal distribution of the disease makes this an important young adult disease and relevant to pediatric radiologists. Staging and response to therapy are key factors in the prognosis of the disease. Familiarity with the Deauville scoring system for PET/CT response in important for the pediatric radiologist to be a valuable team member in the care of these patients.


Additional Resources:

A broad group of soft tissue tumors the pediatric radiologist is frequently consulted to review MRI findings and CT findings for initial staging. Further consultation to consider lymphoscintigraphy to evaluate for extent of surgery and nodal disseciton as well as to comment on the value of additional imaging including FDG-PET/CT in some cases.


Additional Resources:

Although considered a rare pediatric tumor, thyroid cancer is an important one to recognize for the pediatric radiologist. The radiologist is a key player in both diagnosis and treatment for these patients from the initial ultrasound to FNA biopsy and finally to determining the need for radioiodine therapy. With the release of dedicated pediatric guidelines from the American Thyroid Association, we must be familiar with new pediatric-specific recommendations.


Additional Resources:

Oncology Committee Roster


Adina L. Alazraki, MD, Chair
Susan E. Sharp, MD, Vice Chair
Kevin B. Cederberg, MD
Heike E. Daldrup-Link, MD, PhD
James C. Davis, MD
Kelly R. Dietz, MD
Jonathan R. Dillman, MD, MSc
Meryle Eklund, MD
Anne Gill, MD
Alok I. Jaju, MD
Geetika Khanna, MD
M. Beth McCarville, MD
Ross A. Myers, MD
Erika Pace, MD
Marguerite T. Parisi, MD, MS
Jing  Qi, MD
Barry L. Shulkin, MD, MBA
Marilyn J. Siegel, MD, FACR
Shaikh Sikandar, DNB,EDIR
Sudha P. Singh, MD, MBBS
Judy H. Squires, MD
Lisa J. States, MD
Alexander J. Towbin, MD
Pankaj  Watal, MD

SPR Oncology Presentations



 View the Oncology presentations from the SPR 2018 Annual Meeting & Postgraduate Course.

Click here to view